<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03271450</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000215</org_study_id>
    <nct_id>NCT03271450</nct_id>
  </id_info>
  <brief_title>The DARE Warfarin CER Study</brief_title>
  <official_title>The Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Warfarin Comparative Effectiveness Research Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately half a million Americans annually experience venous thromboembolic disease,
      including deep venous thrombosis (DVT) and pulmonary embolism (PE). Since 2010, four new oral
      anticoagulants have been approved for marketing in addition to the vitamin K antagonist
      warfarin. Very limited head-to-head data exists comparing these treatment options, leaving
      patients, clinicians, and other stakeholders with little guidance for selecting the best
      strategy that balances recurrence reduction with risk of bleeding. In the DARE Warfarin CER
      Study, the researchers compare all five currently available oral anticoagulant agents for the
      extended treatment of DVT and PE, as well as no extended treatment. This study also aims to
      evaluate whether treatment heterogeneity exists for specific populations, such as older
      patients or those with renal dysfunction. In a secondary aim, the study will also leverage a
      database of linked electronic health record-insurance claims to validate diagnosis
      definitions and account for potential residual confounding by factors unmeasured in claims
      data. As the patient population includes all Medicare novel anticoagulant users and large
      numbers of commercially insured and Medicaid patients, the results will likely be
      transportable to the majority of US patients experiencing a DVT or PE. Pursuant to the
      objectives of the Patient-Centered Outcomes Research Institute, a study advisory committee
      consisting of key stakeholders will be actively involved in the study design and
      dissemination of results.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Safety Outcome: Intracranial bleed, Gastrointestinal bleed, Other Major bleed</measure>
    <time_frame>1-2 Years</time_frame>
    <description>Defined as a new episode of either Intracranial bleed, Gastrointestinal bleed or another Major bleed event during follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite Effectiveness Outcome: Deep Venous Thrombosis, Pulmonary Embolism</measure>
    <time_frame>1-2 Years</time_frame>
    <description>Defined as a new episode of either Deep Venous Thrombosis or Pulmonary Embolism during follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1-2 Years</time_frame>
    <description>Measured after index prescription date + 90 days and on date on which the event occurred</description>
  </primary_outcome>
  <number_of_groups>30</number_of_groups>
  <enrollment type="Anticipated">416000</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 90 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 180 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuer at 270 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Edoxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 90 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 180 Days: Warfarin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuer at 270 Days: Warfarin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Dabigatran</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Dabigatran</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Dabigatran</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Apixaban</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Apixaban</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Apixaban</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Rivaroxaban</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Rivaroxaban</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Rivaroxaban</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Edoxaban</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Edoxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Edoxaban</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Edoxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Edoxaban</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Edoxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin: extended treatment (e.g at least 90 days)</intervention_name>
    <description>90 days</description>
    <arm_group_label>Continuer at 90 Days: Warfarin</arm_group_label>
    <arm_group_label>Discontinuer at 90 Days: Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin: extended treatment (e.g at least 180 days)</intervention_name>
    <description>180 days</description>
    <arm_group_label>Continuer at 180 Days: Warfarin</arm_group_label>
    <arm_group_label>Discontinuer at 180 Days: Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin: extended treatment (e.g at least 270 days)</intervention_name>
    <description>270 days</description>
    <arm_group_label>Continuer at 270 Days: Warfarin</arm_group_label>
    <arm_group_label>Discontinuer at 270 Days: Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort derived from a commercial database, MarketScan, and Medicare Research Identifiable
        Files using data from 2009-2015. Cohort data will be updated as new data come in through
        2019.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient stay with diagnosis code of DVT/PE, for which the patient has at least 365
             days continuous medical and pharmacy eligibility prior and no other inpatient stays
             with DVT/PE diagnosis. Set discharge date as index diagnosis date. Patients can enter
             the cohort only once (not multiple times).

          -  Prescription fill for an anticoagulant ([generic name=dabigatran, apixaban ,
             rivaroxaban, edoxaban, or warfarin ) ] within 7 days of and including index diagnosis
             date. Set earliest anticoagulant prescription as index generic and index rx date.

          -  No anticoagulant prescription fill in the 365 days prior to index diagnosis date.

          -  Continuous use of an anticoagulant for the first 90 days including and following the
             index rx date, defined as no gaps in therapy &gt;7 days. For each patient, assign a
             variable to indicate whether the patient filled any other anticoagulants during this
             period.

        Exclusion Criteria:

          -  Any safety outcome between index diagnosis date and index rx date + 90, defined as:
             intracranial bleed, gastrointestinal bleed, or other major bleed.

          -  Any DVT/PE between index diagnosis date and index rx date + 90
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Joshua J Gagne</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dabigatran</keyword>
  <keyword>warfarin</keyword>
  <keyword>apixaban</keyword>
  <keyword>edoxaban</keyword>
  <keyword>extended treatment</keyword>
  <keyword>oral anticoagulant</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>comparative safety</keyword>
  <keyword>comparative effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

